Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis-Reference-Cited by-同舟云学术

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

Published:2015-04 Issue:4 Volume:35 Page:412-423
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Dulai Parambir S.¹²,Mosli Mahmoud¹³⁴,Khanna Reena¹³,Levesque Barrett G.¹²,Sandborn William J.¹²,Feagan Brian G.¹³

Affiliation:

1. Robarts Clinical Trials; Robarts Research Institute; Western University; London Ontario Canada

2. Division of Gastroenterology; University of California San Diego; La Jolla California

3. Department of Medicine; Western University; London Ontario Canada

4. Department of Medicine; King Abdulaziz University; Jeddah Saudi Arabia

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/phar.1561/fullpdf

Reference47 articles.

1. Inflammatory bowel disease;Abraham;N Engl J Med,2009

2. Ulcerative colitis;Ordas;Lancet,2012

3. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis;Danese;Aliment Pharmacol Ther,2014

4. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews;Feagan;Inflamm Bowel Dis,2013

5. Oral budesonide for induction of remission in ulcerative colitis;Sherlock;Cochrane Database Syst Rev,2010

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of upadacitinib in a child with refractory ulcerative colitis;Meditsinskiy sovet = Medical Council;2024-09-02

2. Short term effectiveness of ustekinumab versus vedolizumab in Crohn’s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis;Saudi Journal of Gastroenterology;2024-08-19

3. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment;BMC Gastroenterology;2022-03-27

4. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis;Journal of Crohn's and Colitis;2020-01-04

5. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence;Current Medical Research and Opinion;2019-07-19